D. E. Shaw & Co., Inc. Satsuma Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $46,612 - $70,087	-11,232 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $15,417 - $24,349	-3,396 Reduced 23.22%	11,232 $52,000
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $70,214 - $106,053	14,628 New	14,628 $103,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.